Respiratory News and Research RSS Feed - Respiratory News and Research

Meda reaches agreement with Valeant to terminate joint ventures

Meda reaches agreement with Valeant to terminate joint ventures

Meda has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates have been established. [More]
First Edition: April 7, 2014

First Edition: April 7, 2014

Today's headlines include stories about the next round of health law challenges the Obama administration faces as well as the new Medicare Advantage rates scheduled to be announced today. [More]
1/3 of ICU patients develop depression that typically manifests as physical symptoms

1/3 of ICU patients develop depression that typically manifests as physical symptoms

A third of intensive care patients develop depression that typically manifests as physical, or somatic, symptoms such as weakness, appetite change, and fatigue, rather than psychological symptoms, according to one of the largest studies to investigate the mental health and functional outcomes of survivors of critical care, published in The Lancet Respiratory Medicine. [More]
A novel device for inhalation drug delivery

A novel device for inhalation drug delivery

Inhalation is an increasingly important route for non-invasive drug delivery for both systemic and local applications. Control of particle size and output plays a critical role in the efficient and effective delivery of oft en expensive medications to the lung. [More]

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]
Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Research and Markets has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. [More]
Rural nursing presents challenges, rewards

Rural nursing presents challenges, rewards

Providing comprehensive health care can be a daunting task for nurses serving nearly 60 million people living in rural America. [More]

Walgreens' March sales up 4.5% to $6.43 billion

Walgreens had March sales of $6.43 billion, an increase of 4.5 percent from $6.16 billion for the same month in fiscal 2013. [More]

New "3D" method could reduce the need for animal testing

To determine whether new medicines are safe and effective for humans, researchers must first test them in animals, which is costly and time-consuming, as well as ethically challenging. [More]
BronchoGen genomic test meets primary endpoint in AEGIS-2 clinical trial

BronchoGen genomic test meets primary endpoint in AEGIS-2 clinical trial

Allegro Diagnostics Corp. today announced that the AEGIS-2 clinical trial has met its primary endpoint, demonstrating that the BronchoGen genomic test improves the accuracy of lung cancer diagnosis when used in combination with bronchoscopy. [More]
FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 10 through 64 years of age. [More]
CDC receives 2014 Franz Edelman Award for Achievement in Operations Research and Management Sciences

CDC receives 2014 Franz Edelman Award for Achievement in Operations Research and Management Sciences

​The U.S. Centers for Disease Control and Prevention (CDC), which collaborated with Kid Risk, Inc. to use analytics and operations research to combat the remaining pockets of polio around the world, last night won the 2014 Franz Edelman Award for Achievement in Operations Research and the Management Sciences at a banquet sponsored by the Institute for Operations Research and the Management Sciences (INFORMS) in Boston. [More]
Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS. [More]
Actavis announces acquisition of Silom Medical for $100 million

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. [More]

Risk of preterm births is 27% higher during high temperatures

When temperatures reach 32°C or higher over a period of four to seven days, the risk of early-term delivery is 27% higher than on typical summer days, according to a study led by Nathalie Auger of the University of Montreal's Department of Social and Preventive Medicine. [More]

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"). [More]

CDC receives 2014 Franz Edelman Award for Achievement in Operations Research, Management Sciences

The U.S. Centers for Disease Control and Prevention (CDC), which collaborated with Kid Risk, Inc. to use analytics and operations research to combat the remaining pockets of polio around the world, tonight won the 2014 Franz Edelman Award for Achievement in Operations Research and the Management Sciences at a banquet sponsored by the Institute for Operations Research and the Management Sciences (INFORMS) in Boston. [More]

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]

Extreme summer heat in Montreal may have effect on early-term deliveries

When temperatures reach 32-C or higher over a period of four to seven days, the risk of early-term delivery is 27% higher than on typical summer days, according to a study led by Nathalie Auger of the University of Montreal's Department of Social and Preventive Medicine. The study involved data from 300,000 births that took place in Montreal between 1981 to 2010 with summer temperatures recorded by Environment Canada during this period. Auger is also affiliated with the university's CHUM Superhospital Research Centre. [More]